Zeitschrift für klinische und experimentelle Pathologie

Abstrakt

Triple Negative Breast Cancer in Southeast Nigeria: A Review of 149 Cases; What is New?

Nzegwu Martin Arinzechukwu, Uzoigwe Joseph, Babatunde Omotowo, Nwokoro Onyekachi, Nnamani Sunday, Enemuo Vincent C, Sule Emmanuel, Nzegwu Victor Ifeanyichukwu, Nzegwu Christie Okhen, Nwoye Ogochukwu, Aniume Onyekachi, Edeh Anthony, Ozumba B C, Oruamade Isioma, Okwulehi Vincent

Purpose: To determine the prevalence of Triple Negative Breast Cancer (TNBC) and its features. Second highlight what is new and applicable in our setting.

Material and methods: Data of all immunohistochemical typed blocks for breast cancer was pulled and only those negative for Estrogen Receptor (ER), Progesterone Receptor (PgR) and Her 2 Neuro Receptor (HER-2) amplification were used.

Results: Of 417 breast specimens in 3-years with ER negative, PgR negative and Her-2 amplification negative, 149 (35.7%) were TNBC. 143 were females 96% and 6 were males 4%. Median age was in the 31-40 years. Most presented at a late stage as in many other cases 48 (32% presenting at stage 4 while 47 (31.5%) presented at stage 3, 43 (29%) had no clear records so were marked as unknown. Treatment applied was taxane combination chemotherapy, surgery and radiation. Baseline survival data after 5 years stood at 63.5% for stage 2, 59% for stage 3. No stage 4 was seen after 5 years follow up.

Conclusion: Most presented late at stage 3 or 4 as premenopausal and survival was poor at 59% of stage 3. Literature suggests some will benefit from tamoxifen despite TNBC status if they have TP53 mutation.